In 1968 Berson and Yalow reported that plasma parathyroid hormone (PTH) levels determined by the radioimmunoassay were different when the different antiserum was employed, which was the first observation about immunoheterogenity of PTH in human plasma (Berson and Yalow, 1968) . Recently, Silverman and Yalow reported that the difference had been due to the antiserum used and that one had been the antiserum specific for the amino (N) terminal and the other for the carboxyl (C) terminal portion of the PTH molecule (Silverman and Yalow, 1973) .
During this period many papers had been reported from several laboratories about immunoheterogeneity of PTH (Arnoud et al., 1971; Habner et al., 1971; Canterbury et al., 1972; Segre et al., 1972; Goldsmith et al., 1973; Arnaud et al., 1973) and it has become recognized that the usual antisera used for PTH radioimmunoassay were specific mostly for the C-terminal and it had to wait a chance to obtian the antiserum specific for the N-terminal.
However, we have developed the PTH radioimmunoassay specific for the N-terminal by iodinating synthetic 1-34bovine PTH (1-34bTH) and using commercially available antiserum which contains antibodies for both N-and C-terminal portion of PTH. As shown in Fig. 3 , the standard 1-34bPTH showed 10 per cent fall of B/T at dose of 0.01 to 0.03ng/tube in every assay. A dilutional curve of bPTH was parallel to that of 1-34bPTH, but the degree of reactivity of bPTH was 3.4 times less to that of 1-34bPTH, according to an average of 8 assays.
Extract of parathyroid adenoma or plasmas from these patients showed a dilutional curve parallel to that of 1-34bPTH, except that plasma from patients with pseudohypoparathyroidism showed no reaction, indicating less than 0.1ng 1-34bPTH Eq/ml of plasma. Standard curve and dilutional curves of 1-34bPTH , extract of parathyroid adenoma or plasmas from patients with primary hyperparathyroidism, uremia or pseudohypoparathyroidism in C-PTH radioimmunoassay:
As shown in Fig.4 , 1-34bPTH did not show any cross-reactivity at all up to 10 ng/tube. However, the standard bPTH was observed to decrease BIT more than 10 per cent at dose of 0.01 to 0.03ng/tube in every Endocrinol. Japon. December 1975 assay. Extract of parathyroid adenoma or plasmas obtained from these patients showed a parallel dose response curve to that of the standard bPTH. Plasma N-PTH, C-PTH and PTH levels in patients with primary hyperparathyroidism, uremia or pseudohypoparathyroidism:
Plasma N-PTH and C-PTH levels determind by the methods described here were shown in Table 1 with plasma PTH levels obtained by the PTH radioimmunoassay. Plasma N-PTH levels were always lower than plasma C-PTH or PTH levels at a difference of one 4th to 16th, but plasma C-PTH levels were almost in the same range to plasma PTH levels.
In parathyroidal effluent samples plasma levels of N-PTH were almost tiwce to those of C-PTH or PTH.
Plasma N-and C-PTH levels following the removal of parathyroid adenoma: Plasma N-and C-PTH levels were determined prior to and repeatedly following the removal of parathyoid adenoma in 2 patients with primary hyperparathyroidism.
As shown in Fig. 5 , plasma N-PTH levels (0.8 and 1.9ng bPTH Eq/ml) were decreased following the adenoma removal and became undetectable within 10min.
In contrast, plasma C-PTH levels (2.6 and 4.6 ng bPTH Eq/ml) were also decreased after the operation, but disappearance curves were much slower. These data indicated that the half life of N-PTH in human circulation was less than 10min and that of C-PTH 40 and 50min.
Assay variabilities:
Intra-assay and inter-assay variability of each PTH radioimmunoassay were shown in Table 2 and all of these were in reasonable ranges. 
Discussion
Since Berson and Yalow reported immunoheterogeneity of PTH in human plasma (Berson and Yalow, 1968) , the PTH radioimmunoassay in which an antigenic determinant portion locates at a biological active part of PTH has been looked for. It has been known that biological activity of PTH locates at its N-terminal portion (Potts, Jr., 1973) and we have developed a sensitive and specific radioimmunoassay for the Nterminal by iodinating 1-34bPTH. 1-34bPTH is known to contain no tyrosine in its amino-acid sequence, but the iodination process done by the chloramine-T method brought an iodinated 1-34bPTH which was sufficient to be used for the 1-34PTH radioimmunossay.
As reported previously from our laboratory (Tanaka et al., 1974) , the PTH antisera provided from Wellcome contained antibodies for both bPTH and 1-34bPTH, indicating that these antisera could be used for the 1-34PTH radioimmunoassay with the iodinated 1-34bPTH. However, the amount of antibodies reacted with N-PTH was much less when compared with that of antibodies reacted with C-PTH. Therefore, we had to use much lower antiserum dilution for N-PTH radioimmunoassay. Extract of parathyroid adenoma or plasmas from patients with primary hyperparathyroidism or uremia showed a dilutional curve parallel to that of 1-34bPTH, indicating immunological identity between them. Although a parallelism existed between 1-34bPTH and bPTH, the degree of reactivity of bPTH was 4.3 times less to that of 1-34bPTH. This ratio should be 2.3 when these materials were compared on molar basis, which might indicate that about one half of the bPTH used here lacks the N-teaminal reactivity.
C-PTH radioimmunoassay was developed according to the method reported by Segre et al. (Segre et al., 1972) . 1-34bPTH added to the PTH radioimmunoassay system blocked the reaction of 1-34bPTH up to 10ng/tube, indicating that plasma 1-34PTH Endocrinol.
Japon. December 1975 levels should be over 100ng/ml to be detected as C-PTH in this system, but, the standard bPTH was possible to be detected down to 0.3ng/ml.
Extract of parathyroid adenoma or plasmas from patients with primary hyperparathyroidism, uremia or pseudohypoparathyroidism showed a parallel dose response curve to that of the standard bPTH.
These observations indicate that PTH whose antigenic determinant portion does not locate within 1-34portion of PTH molecule can be determined by use of this radioimmunoassay system.
By employing both N-PTH and C-PTH radioimmunoassay in conjunction with the PTH radioimmunoassay, plasma PTHs levels in patients with primary hyperparathyroidism, uremia or pseudohypoparathyroidism were measured. It was found that plasma N-PTH levels were much lower than plasma C-PTH or PTH levels and that plasma N-PTH levels were only one 4th to 16th of plasma C-PTH, when bPTH was used as the standard.
As one half of the bPTH used here lacks the N-terminal activity, this ratio would be one 8th to 32th, suggesting that about 90% of peripheral plasma PTH levels determined by the PTH radioimmunoassay could be biologically inactive. Plasma levels of C-PTH were in the same range to those of PTH, suggesting that most of PTH determined by our PTH radioimmunoassay were PTH whose antigenic determinant portion located at the part other than vations coincide with those reported by Segre et al. (Segre et al., 1972) .
It is interesting to note that the parathyroid effluent bloods obtained from patients with parathyroid adenoma showed higher levels of plasma N-PTH than those of C-PTH or PTH. The ratios N-PTH to C-PTH or PTH were 2.4 and 1.7. However, when based on the fact that about half of the bPTH standard lacks the N-terminal reactivity, these levels could turn out to be about equal, which suggests that PTH with 
